We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00998335
Recruitment Status : Completed
First Posted : October 20, 2009
Results First Posted : July 29, 2016
Last Update Posted : September 28, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:

The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (NAFLD) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir (Levemir®) or aspart (Novolog®). This study is to determine the effect on hepatic steatosis and insulin secretion/action of lowering the fasting plasma glucose (FPG) to target with once daily basal insulin detemir alone or combining insulin detemir with premeal insulin aspart in patients with uncontrolled type 2 diabetes mellitus (T2DM).

In the first 3 months the investigators will optimize metabolic control in all patients with intensive basal (bedtime) detemir insulin aiming at a normal fasting plasma glucose. After this treatment period, patients will be randomized in the second 3 months in a 2:1 ratio to insulin detemir or detemir plus aspart. The investigators propose that insulin will improve day-long glycemic control and A1c, reduce hepatic steatosis (NAFLD) (primary endpoint) and insulin secretion/sensitivity being well tolerated while causing minimal weight gain and hypoglycemia (secondary endpoints). The study will allow to assess if there is an additional benefit of adding pre-meal rapid-acting insulin aspart to basal insulin to these endpoints.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: Long-acting bedtime insulin detemir (Levemir) Drug: Insulin detemir and pre-meal insulin aspart. Phase 4

Detailed Description:

The control of hyperglycemia in T2DM ameliorates the metabolic abnormalities of T2DM but whether this improves hepatic steatosis has not been examined carefully with the use of improved insulin formulations (long-acting insulins detemir or glargine, alone or combined with pre-meal short-acting insulins). Most research studies have focused on glycemic control without a careful examination to the underlying mechanisms, with some of these studies reporting on improved hepatic and muscle insulin sensitivity. The investigators have found in the laboratory that intensified insulin therapy in T2DM is associated with enhanced glycogen synthase fractional velocity and non-oxidative glucose disposal, but with no improvement at the level of insulin-stimulated insulin receptor tyrosine phosphorylation, hexokinase II mRNA or enzyme function, phosphatidylinositol 3-kinase (PI 3-kinase) associated with IRS-1, or Akt phosphorylation. Our work did not examine hepatic steatosis or insulin secretion/action, nor was designed to distinguish between the relative contribution of reduced glucotoxicity on insulin sensitivity vs. beta-cell function from pre-meal regular vs. NPH insulin. It is possible that the beneficial effects of insulin therapy of reduced plasma glucose and FFA concentrations may be offset by excessive hyperinsulinemia and weight gain from the use of insulins with suboptimal pharmacokinetics compared to the newer insulin formulations.

Insulin detemir is an insulin analogue approved in 2005 by the FDA. It is a long-acting insulin analogue that has shown to be more predictable in achieving therapeutic plasma insulin levels compared to NPH insulin. This is associated with several clinical benefits, such as better glycemic control, less hypoglycemia, modest weight gain and better quality of life for patients with type 2 diabetes. If gluco-lipotoxicity likely play an important role in the development of hepatic steatosis (NAFLD) in T2DM the investigators speculate that if reversed by a strategy of basal long-acting insulin (insulin detemir) alone, or combined with a rapid-acting analog (pre-meal insulin aspart) may be a good strategy for the treatment of T2DM.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes
Study Start Date : June 2007
Primary Completion Date : February 2010
Study Completion Date : February 2010

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Insulin detemir only
Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
Drug: Long-acting bedtime insulin detemir (Levemir)
This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
Other Name: Levemir insulin (trademark insulin by Novo Nordisk)
Experimental: Insulin detemir plus aspart
After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
Drug: Insulin detemir and pre-meal insulin aspart.
This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
Other Names:
  • Insulin detemir = Levemir (Novo Nordisk)
  • Insulin aspart = Novolog (Novo Nordisk)

Outcome Measures

Primary Outcome Measures :
  1. Hepatic Steatosis [ Time Frame: 3 and 6 months ]
    Hepatic steatosis measured by proton magnetic resonance spectroscopy (1H-MRS).

Secondary Outcome Measures :
  1. Metabolic Control as Measured by the A1c [ Time Frame: 3 and 6 months ]
  2. Change in Insulin Secretion [ Time Frame: 3 and 6 months. ]
    Derived from the hyperglycemic clamp (Plasma C-peptide change vs. pretreatment in first and second phase).

  3. Intramyocellular (IMCL) by Magnetic Resonance Imaging and Spectroscopy (MRS). [ Time Frame: 3 and 6 months. ]
    Percent intramyocellular (IMCL) by magnetic resonance imaging and spectroscopy (MRS).

  4. Plasma Lipid Concentration. [ Time Frame: 3 and 6 months. ]
    Fasting plasma lipid concentration on day of admission at 3 and 6 months.

  5. Change in Anthropometric Measure (Body Weight). [ Time Frame: 3 and 6 months. ]
    Change in anthropometric measure (body weight) done on day of admission at 3 and 6 months.

  6. Number of Hypoglycemic Events [ Time Frame: 3 and 6 months ]
    Defined as hypoglycemia <40 mg/dl and/or requiring medical assistance during the trial.

  7. Metabolic Control as Measured by the Fasting Plasma Glucose Concentration [ Time Frame: 3 and 6 months ]
  8. Metabolic Control as Measured by the Postprandial Plasma Glucose During the Day-long Plasma Glucose Profile. [ Time Frame: 3 and 6 months ]
  9. Advanced Lipid Testing [ Time Frame: 3 and 6 months ]
    Change in lipoprotein particle number was determined using NMR.

  10. Change in Anthropometric Measure (Body Mass Index [BMI]). [ Time Frame: 3 and 6 months. ]
    Change in anthropometric measure (body mass index [BMI]) done on day of admission at 3 and 6 months.

  11. Percent Change From Baseline in Vascular Inflammatory Markers [ Time Frame: 3 and 6 months ]
    Inflammatory Markers include: Adiponectin, MMP-9, E-selectin, sICAM, and sVCAM

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

To participate patients must:

  1. Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.
  2. Female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period.
  3. Age range of 18 to 70 years (inclusive).
  4. Patients must have been on a stable dose of allowed chronic medications for two months prior to entering the double-blind treatment period.
  5. All participants must have the following laboratory values:

    • Hemoglobin ≥ 12 g/dl in males or ≥ 11 g/dl in females
    • Serum creatinine ≤ 1.5 mg/dl
    • AST (SGOT) ≤ 2.5 times upper limit of normal
    • ALT (SGPT) ≤ 2.5 times upper limit of normal
    • Alkaline phosphatase ≤ 2.5 times upper limit of normal

Exclusion Criteria:

Patients will be excluded if any of the following criteria are present:

  1. Individuals with type 1 diabetes or type 2 diabetes and a FPG ≥ 300 mg/dl.
  2. Subjects on sulfonylureas, metformin and/or TZDs unless the dose has been stable for at least 2 months prior to study entry.
  3. Patients on any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on stable doses of such agents for the past two months before entry into the study. Patients may be taking stable doses of estrogens or other hormonal replacement therapy if the patient has been on these agents for the prior two months. Patients taking systemic glucocorticoids will be excluded.
  4. Past (within 1 year) or current history of alcohol abuse.
  5. Patients will be excluded if there is a history of clinically significant heart disease (New York Heart Classification greater than grade II), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) or chronic renal failure (serum creatinine greater than 1.5 mg/dl).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00998335

United States, Texas
The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital
San Antonio, Texas, United States, 78229-3900
Sponsors and Collaborators
University of Florida
VA Office of Research and Development
Novo Nordisk A/S
Principal Investigator: Kenneth Cusi, M.D. University of Flordia
More Information

Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT00998335     History of Changes
Other Study ID Numbers: 20060167
First Posted: October 20, 2009    Key Record Dates
Results First Posted: July 29, 2016
Last Update Posted: September 28, 2016
Last Verified: June 2016

Keywords provided by University of Florida:
Type 2 diabetes mellitus
Insulin therapy
Detemir (Levemir)
Aspart (Novolog)
Hepatic steatosis

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin degludec, insulin aspart drug combination
Insulin Aspart
Insulin, Long-Acting
Insulin Detemir
Hypoglycemic Agents
Physiological Effects of Drugs